Neurocrine lay-offs are related to the FDA rejection of their would-be blockbuster, Indiplon. Check out the stock chart for NBIX. First big drop is when FDA made the announcement, second drop is when Pfizer (as a result of the rejection) decided to stop working with them. If there is a single lay-off story that has absolutely nothing to do with the economy or the housing market, then this is it.
